Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma

被引：120

作者：

Bronte, Giuseppe ^{[1
]}

Rizzo, Sergio ^{[1
]}

La Paglia, Laura ^{[1
]}

Adamo, Vincenzo ^{[2
]}

Siragusa, Sergio ^{[3
]}

Ficorella, Corrado ^{[4
]}

Santini, Daniele ^{[5
]}

Bazan, Viviana ^{[1
]}

Colucci, Giuseppe ^{[6
]}

Gebbia, Nicola ^{[1
]}

Russo, Antonio ^{[1
]}

机构：

[1] Univ Palermo, Dept Surg & Oncol Sci, Sect Med Oncol, Palermo, Italy

[2] Univ Policlin G Martino Messina, Med Oncol & Integrated Therapies Unit, Messina, Italy

[3] Azienda Osped Univ Policlin P Giaccone, Chair & Unit Hematol Transplant, Palermo, Italy

[4] Univ Aquila, Dept Expt Med, I-67100 Laquila, Italy

[5] Univ Campus Biomed, Rome, Italy

[6] Canc Inst Giovanni Paolo II, Med & Expt Oncol Unit, Bari, Italy

来源：

CANCER TREATMENT REVIEWS | 2010年 / 36卷

关键词：

EGER; Driver mutations; Tyrosine kinase inhibitors; GROWTH-FACTOR-RECEPTOR; EML4-ALK FUSION GENE; PREVIOUSLY TREATED PATIENTS; TYROSINE KINASE INHIBITOR; K-RAS MUTATIONS; EGFR MUTATIONS; CANCER PATIENTS; GEFITINIB SENSITIVITY; ACTIVATING MUTATIONS; ACQUIRED-RESISTANCE;

D O I：

10.1016/S0305-7372(10)70016-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The adenocarcinoma of the lung has recently shown peculiar molecular characteristics, which relate with both carcinogenesis and response to targeted drugs. Several molecular alterations have been defined as "driver mutations". These are responsible for both the initiation and maintenance of the malignancy. The epidermal growth factor receptor (EGFR) pathway is the main regulator of cell function and cancer development. It has a widely defined role in the occurrence of driver mutations. Up till now EGFR gene mutations, KRAS gene mutations and EML4-ALK fusion genes are the most widely recognized alterations involved in both the biology and the clinical management of lung adenocarcinoma. In this review we report the molecular bases that have led to the clinical application of the detection for such genetic impairments. Subsequently we discuss the clinical studies regarding the prognostic role and the predictive value for response to anti-EGFR tyrosine kinase inhibitors (TKI) of the same mutations. We also provide a potential algorithm as a guide in the choice of the best treatment for patients with adenocarcinoma. (C) 2010 Elsevier Ltd. All rights reserved.

引用

页码：S21 / S29

页数：9

共 87 条

[1]

[Anonymous], J CLIN ONCOL

[2] Ras activation of the Raf kinase: Tyrosine kinase recruitment of the MAP kinase cascade [J].

Avruch, J ;

Khokhlatchev, A ;

Kyriakis, JM ;

Luo, ZJ ;

Tzivion, G ;

Vavvas, D ;

Zhang, XF .

RECENT PROGRESS IN HORMONE RESEARCH, VOL 56, 2001, 56 :127-155

[3] Epidermal Growth Factor Receptor Mutations in Plasma DNA Samples Predict Tumor Response in Chinese Patients With Stages IIIB to IV Non-Small-Cell Lung Cancer [J].

Bai, Hua ;

Mao, Li ;

Wang, Hang Shu ;

Zhao, Jun ;

Yang, Lu ;

An, Tong Tong ;

Wang, Xin ;

Duan, Chun Jian ;

Wu, Na Mei ;

Guo, Zhi Qing ;

Liu, Yi Xu ;

Liu, Hong Ning ;

Wang, Ye Yu ;

Wang, Jie .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (16) :2653-2659

[4] Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor - Mutant lung adenocarcinomas with acquired resistance to kinase inhibitors [J].

Balak, Marissa N. ;

Gong, Yixuan ;

Riely, Gregory J. ;

Somwar, Romel ;

Li, Allan R. ;

Zakowski, Maureen F. ;

Chiang, Anne ;

Yang, Guangli ;

Ouerfelli, Ouathek ;

Kris, Mark G. ;

Ladanyi, Marc ;

Miller, Vincent A. ;

Pao, William .

CLINICAL CANCER RESEARCH, 2006, 12 (21) :6494-6501

[5] The epidermal growth factor receptor family [J].

Bazley, LA ;

Gullick, WJ .

[6]

BOS JL, 1989, CANCER RES, V49, P4682

[7]

Brose MS, 2002, CANCER RES, V62, P6997

[8]

Brugger W, 2009, J CLIN ONCOL, V27

[9] Oncogenic Ras and its role in tumor cell invasion and metastasis [J].

Campbell, PM ;

Der, CJ .

SEMINARS IN CANCER BIOLOGY, 2004, 14 (02) :105-114

[10] Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer [J].

Cappuzzo, F ;

Hirsch, FR ;

Rossi, E ;

Bartolini, S ;

Ceresoli, GL ;

Bemis, L ;

Haney, J ;

Witta, S ;

Danenberg, K ;

Domenichini, I ;

Ludovini, V ;

Magrini, E ;

Gregorc, V ;

Doglioni, C ;

Sidoni, A ;

Tonato, M ;

Franklin, WA ;

Crino, L ;

Bunn, PA ;

Varella-Garcia, M .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (09) :643-655

← 1 2 3 4 5 6 7 8 9 →